Product Description
Belnacasan prevents the activation of a particular enzyme, Caspase-1, which plays a major role in activating this damaging immune response brought on by COVID-19. The goal of this medication being a more targeted treatment that aims to prevent the devastating immune response. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05164120)
Mechanisms of Action: CAAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psoriasis|Epilepsies, Partial|COVID-19|Epilepsy
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| MedStar-COVID-19-belnacasan | P2 |
Completed |
COVID-19 |
2022-07-18 |
2024-09-20 |
Patient Enrollment|Primary Endpoints|Treatments |
|
| 2011-004156-19 | P2 |
Completed |
Epilepsy |
2013-09-24 |
2025-06-06 |
Treatments |
|
| VX11-765-402 | P2 |
Terminated |
Epilepsies, Partial |
2013-08-01 |
2019-03-19 |
Treatments |
|
| VX09-765-401 | P2 |
Completed |
Epilepsies, Partial |
2010-11-01 |
2019-03-19 |
Treatments |
|
| 2004-000283-27 | P2 |
Completed |
Unknown |
2005-06-13 |
2022-03-12 |
Treatments |
|
| VX04-765-301 | P2 |
Completed |
Psoriasis |
None |
2019-03-21 |
Treatments |